Microscopy provides visual and spatial evidence for particles, crystal habit, contaminants, product failures, thermal behavior, and surface features.
This decision-focused guide explains the scientific measurement basis, when to use it, its limitations, sample amount considerations, competing methods, FDA-facing concerns, and common mistakes.
Microscopy includes optical microscopy, polarized light microscopy, SEM, hot-stage microscopy, and AFM. These methods visualize particles, surfaces, crystal habit, inclusions, birefringence, thermal behavior, and topography.
Use microscopy for contaminant triage, particle-shape analysis, crystal habit, formulation failure, coating defects, agglomeration, birefringence, thermal microscopy, SEM/EDX localization, and morphology-linked process issues.
Microscopy is local and can be non-representative. Visual similarity does not prove chemical identity or solid form. SEM may require vacuum, coating, cutting, or other prep; AFM scans small areas slowly; hot-stage experiments can create artifacts.
Amounts can be very small for triage or imaging, but representative sampling may require multiple particles, regions, or lots. SEM/EDX, image analysis, and cGMP methods should be scoped against the decision and matrix.
XRPD, Raman/FTIR microscopy, particle-size analysis, elemental analysis, chromatography, NMR, and thermal analysis compete or complement microscopy depending on whether the unknown is form, chemistry, particle size, or morphology.
FDA cares whether the microscopy method is representative, documented, specific for the stated quality attribute, and supported by orthogonal identity data when the result affects release, investigation, or CMC decisions.
Common mistakes include selecting only visually interesting particles, ignoring sampling statistics, using images as proof of composition, changing particles during prep, and reporting beautiful images without explaining the development decision.
Triclinic uses microscopy to connect visible particle, crystal, contaminant, and surface features to practical material behavior. Real-world applications include foreign-particle investigations, morphology comparisons, birefringence and crystallinity checks, hot-stage observations, agglomeration or attrition assessments, and SEM/optical evidence that helps explain processing, stability, dissolution, or lot-comparability concerns.
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Stereo / compound / polarized-light microscopy | Leica M80 stereo microscope; Leica DM2500P compound microscope; polarizing-light microscope; Pax-it2! v.1.4.3 software | Still and dynamic image capture, birefringence, morphology, particle habit, density/color/shape, and optical-path boundary observations. |
| Digital microscopy and topography | Keyence VHX-2000E digital microscope | Still imaging, topography image capture, surface inspection, particle documentation, and visual root-cause support. |
| SEM/EDX | Thermo Phenom XL with fully integrated EDX and BSE detector | High-vacuum/low-vacuum SEM imaging, BSE contrast, and integrated elemental analysis for particles and contaminants. |
| Field-emission SEM | FEI Quanta 3D FEG with high-vacuum, low-vacuum, and cryo capability | High-resolution morphology, surface/ultrastructure examination, and cryogenic or low-vacuum imaging workflows. |
| EDX detector system | Oxford INCA PentFETx3 EDX | Elemental spectra, spot/region analysis, and elemental maps for foreign-particle and contaminant investigations. |
| Hot-stage microscopy | Linkam LTS420, ambient to 600 °C | Thermomicroscopy, phase-change observation, melting/recrystallization behavior, and cocrystal/solid-form screening support. |
| Atomic-force microscopy | Hitachi and Park AFM systems, all modes | Nanometer-scale topography and surface-property measurements for small particles and surfaces. |
| Infrared imaging microscopy | Thermo iN10 MX with Picta 1.5.141 software | IR chemical imaging, ATR/reflection/transmission measurements, microsampling, and component distribution mapping. |
This example uses the legacy microscopy page's polarized-light microscopy discussion as the case-study basis. Microscopy is valuable because it provides visual and spatial evidence that other techniques may average away. It can show morphology, crystal habit, particle size and shape, birefringence, inclusions, surface texture, and sample heterogeneity. The table below summarizes how the observations connect to decisions.
| Microscopy observation | Decision supported |
|---|---|
| Size and shape | Particle morphology, agglomeration, milling effects, or lot-to-lot comparability. |
| Birefringence / anisotropy | Whether particles behave like crystalline, anisotropic material rather than isotropic glass or amorphous material. |
| Crystal habit and interfacial angles | Habit engineering, solid-form screening, process troubleshooting, or crystal-growth interpretation. |
| Surface texture and transparency / opacity | Contaminant triage, coating defects, failure analysis, or material-comparison questions. |
| Localized particles or inclusions | Selection of regions for follow-up Raman, IR, SEM/EDX, XRPD, or other orthogonal testing. |
These examples include technical resources, regulatory guidances, or literature relevant to the technique. Download buttons are placed at the bottom-left of each example.
Author: Melanie Bevill, Chris Seadeek, Nico Setiawan, Shawn Comella, Blaise Mibeck, and Steef Boerrigter
Publication date: November 2023
Abstract: This Triclinic application note links solid-form screening and selection to crystallinity, stability, solubility, hygroscopicity, manufacturability, regulatory needs, and IP objectives. It supports choosing analytical techniques based on the development decision rather than a fixed instrument list.
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: FDA notes that ICH Q2(R2) and Q14 describe validation and development principles for analytical procedures used to assess drug substance and drug product quality. These guidances frame FDA expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence.
Author: Triclinic Labs
Publication date: 2019
Abstract: This white paper describes how low-frequency Raman can distinguish polymorphic forms using lattice-mode information not always available in conventional mid-frequency Raman. It supports using Raman as an orthogonal solid-form tool when XRPD, DSC, or FTIR are inconclusive.
Use this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View techniqueUse this technique when its evidence better matches the sample, matrix, or development decision.
View technique
Tell Triclinic what sample you have, what decision the data must support, what prior data are available, and whether cGMP, release, validation, or regulatory documentation is required.
